# of Displayed Technologies: 1 / 1


Categories

PROTAC-based CDK9 Degraders for Cancer Therapy
TS-075245 — Problem Although cyclin dependent kinase 9 (CDK9) is a promising drug target, traditional small-molecule inhibitors face challenges due to CDK9's structural similarities with other kinases, leading to off-target effects and limited efficacy Solution Applications Advantages Seeking opp…
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Ayinde, Oluwatosin
  • Licensing Officer: He, Panqing

Loading icon